E-GEOD-48403 - Transcription profiling by high throughput sequencing of advanced prostate cancer treated with androgen-deprivation therapy

Released on 7 October 2013, last updated on 23 February 2016
Homo sapiens
Samples (14)
Protocols (3)
Androgen ablation therapy (AAT) is standard treatment for locally-advanced/metastatic prostate cancer (PCa). Many patients develop castration-resistance (CRPCa) after ~2-3 years, with a poor prognosis. The molecular mechanisms underlying CRPCa progression are unclear. mRNA-Seq was performed on tumours from 7 patients with locally-advanced/metastatic PCa before and ~22 weeks after AAT initiation. Differentially regulated genes were identified in treatment pairs. Tumour biopsies from 7 patients were taken before and after AAT treatment
Experiment type
RNA-seq of coding RNA 
Ian Sudbery <ian.sudbery@dpag.ox.ac.uk>, Albiruni R Abdul Razak, Andreas Heger, Chris P Ponting, David Sims, Ernest Mui, Hing Y Leung, Ian D Pedley, Imran Ahmad, Janis Fleming, Joanne Edwards, M M Villasevil, Mark Davis, Owen J Sansom, Prabhaker Rajan, Rhona M McMenemin
Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. Rajan P, Sudbery IM, Villasevil ME, Mui E, Fleming J, Davis M, Ahmad I, Edwards J, Sansom OJ, Sims D, Ponting CP, Heger A, McMenemin RM, Pedley ID, Leung HY. , Europe PMC 24054872
Exp. designProtocolsVariablesProcessedSeq. reads
Investigation descriptionE-GEOD-48403.idf.txt
Sample and data relationshipE-GEOD-48403.sdrf.txt
Additional data (1)E-GEOD-48403.additional.1.zip